Wednesday Feb 26
The Motley Fool
Acadia Pharmaceuticals: Here's What You Should Know About Its Surging Shares
Last year, the FDA agreed to consider the use of just one late stage study as the basis for approving Acadia's new drug, pimavanserin.
Plan to Limit Some Drugs in Medicare Is Criticized
An alliance of drug companies and patient advocates, joined by Democrats and Republicans in Congress, is fiercely opposing an Obama administration proposal that would allow insurers to limit Medicare coverage for certain classes of drugs, including those used to treat depression and schizophrenia.